CSI Market
Sign In | Register

Aura Biosciences Inc (AURA) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access AURA quarterly Cash Flow →
Reviewing cash flow figures over time highlights how Aura Biosciences Inc balances operational cash generation with investment and financing decisions.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Dec 31 2025)
12 Months 		(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-106.19
Depreciation & amortization1.13
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation14.32
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.00
Change In Fair Value Of Derivative Liability-
Marketable Securities Accretion-
Non Cash Lease Expense1.55
Increase Decrease In Operating Lease Liability0.03
Income taxes0.00
Marketable Securities, Gain (Loss), Excluding Other than Temporary Impairments, Total-1.55
Accounts Receivable0.00
Increase (Decrease) in Accounts Payable-0.85
Increase (Decrease) in Accrued Liabilities4.13
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expenses, Other4.03
Other Working Capital0.05
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-1.39
Discontinued operations0.00
Net Cash flow from Operating Activities-84.74
Investing Activities
Capital Expenditures-0.45
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities120.00
Payments to Acquire Marketable Securities-83.96
Real Estate Investments0.00
Proceeds From Sale Of Marketable Securities-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities35.60
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock47.69
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock14.16
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-32.55
Proceeds From Issuance Of Convertible Preferred Stock Deferred-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations32.46
Capital Expenditures Incurred But Not Yet Paid0.09
Remeasurement Of Right Of Use Assets And Lease Liabilities For Lease Modification-
Proceeds From Issuance Of Common Stock Under At The Market Facility Net Of Issuance Costs6.05
Proceeds From Issuance Of Common Stock Warrants From Follow On Offering Net Of Issuance Costs9.25
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities77.16
Effect of exchange rate on cash flow-0.19
Discontinued operations0.00
Free Cash Flow-85.19
Total Cash Flow28.01
4 historic quarters locked

Sign in to unlock the full Aura Biosciences Inc cash flow history.

Sign In Create Free Account

About Aura Biosciences Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-130401

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License